Development and Validation of DM and Pre-DM Risk Prediction Model
NCT ID: NCT04881383
Last Updated: 2024-12-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1014 participants
OBSERVATIONAL
2020-04-01
2023-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Develop a risk prediction function using non-laboratory parameters to predict DM and pre-DM from the data of the HK Population Health Survey 2014/2015
2. Develop a risk scoring algorithm and determine the cut-off score
3. Validate the risk prediction function and determine its sensitivity in predicting DM and pre-DM in PC
Hypothesis to be tested:
The prediction function developed from the Population Health Survey (PHS) 2014/2015 is valid and sensitive in PC.
Design and subjects:
We will develop a risk prediction function for DM and pre-DM using data of 1,857 subjects from the PHS 2014/2015. We will recruit 1014 Chinese adults aged 18-84 from PC clinics to validate the risk prediction function. Each subject will complete an assessment on the relevant risk factors and have a blood test on OGTT and HbA1c on recruitment and at 12 months.
Main outcome measures:
The area under the Receiver operating characteristic (ROC) curve, sensitivity and specificity of the prediction function.
Data analysis and expected results:
Machine learning and Logistic regressions will be used to develop the best model. ROC curve will be used to determine the cut-off score. Sensitivity and specificity will be determined by descriptive statistics. A new HK Chinese general population specific risk prediction function will enable early case finding and intervention to prevent DM and DM complications in PC.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients from Primary Care Clinics
Participating Chinese adults aged 18-84 from Primary Care clinics to validate the risk prediction function. Each subject will complete an assessment on the relevant risk factors and have a blood test on OGTT and HbA1c on recruitment and at 12 months.
OGTT and HbA1c
An investigation form will be given to the patient to attend an approved private laboratory for blood pressure, weight, height, waist and hip circumferences, and a blood test on OGTT, HbA1c, complete blood count (CBC) and lipid profile within three months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
OGTT and HbA1c
An investigation form will be given to the patient to attend an approved private laboratory for blood pressure, weight, height, waist and hip circumferences, and a blood test on OGTT, HbA1c, complete blood count (CBC) and lipid profile within three months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Completed the health examination including physical measurements (body height, weight, BMI, waist and hip circumference) and blood tests (fasting plasma glucose, HbA1c and lipid profile) during PHS 2014/2015
* aged 18-84 years
* Chinese
* aged 18-84 years
* Can communicate in Chinese
* Consent to participate in the study
Exclusion Criteria
* Doctor-diagnosed high blood glucose
* Doctor-diagnosed cardiovascular disease (coronary heart disease, stroke)
* Doctor-diagnosed cancer
* Doctor-diagnosed chronic kidney disease
* Doctor-diagnosed anaemia
(Validation study)
* Doctor-diagnosed DM
* Doctor-diagnosed high blood glucose
* Doctor-diagnosed cardiovascular disease (coronary heart disease, stroke)
* Doctor-diagnosed cancer
* Doctor-diagnosed chronic kidney disease
* Doctor-diagnosed anaemia
* Inability to complete the survey or blood test because of sickness or cognitive impairment
* Do not give consent to the study
18 Years
84 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The University of Hong Kong
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Professor Cindy L.K. Lam
Danny D. B. Ho Professor in Family Medicine and Head of Department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cindy LK Lam, MD
Role: PRINCIPAL_INVESTIGATOR
Department of Family Medicine and Primary Care, University of Hong Kong
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Family Medicine & Primary Care, LKS Faculty of Medicine, University of Hong Kong
Hong Kong, , Hong Kong
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Dong W, Cheng WHG, Tse ETY, Mi Y, Wong CKH, Tang EHM, Yu EYT, Chin WY, Bedford LE, Ko WWK, Chao DVK, Tan KCB, Lam CLK. Development and validation of a diabetes mellitus and prediabetes risk prediction function for case finding in primary care in Hong Kong: a cross-sectional study and a prospective study protocol paper. BMJ Open. 2022 May 24;12(5):e059430. doi: 10.1136/bmjopen-2021-059430.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UW19-831
Identifier Type: -
Identifier Source: org_study_id